Evolent Health Inc (EVH) Shares Sold by Perceptive Advisors LLC
Perceptive Advisors LLC reduced its stake in Evolent Health Inc (NYSE:EVH) by 20.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 850,000 shares of the technology company’s stock after selling 224,327 shares during the period. Perceptive Advisors LLC owned about 1.24% of Evolent Health worth $15,130,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds also recently bought and sold shares of the company. ETF Managers Group LLC acquired a new stake in shares of Evolent Health in the 2nd quarter valued at approximately $102,000. BNP Paribas Arbitrage SA boosted its stake in shares of Evolent Health by 815.4% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,751 shares of the technology company’s stock valued at $120,000 after purchasing an additional 4,232 shares in the last quarter. First Mercantile Trust Co. acquired a new stake in shares of Evolent Health in the 2nd quarter valued at approximately $198,000. Royal Bank of Canada boosted its stake in shares of Evolent Health by 1,197.8% in the 2nd quarter. Royal Bank of Canada now owns 8,293 shares of the technology company’s stock valued at $210,000 after purchasing an additional 7,654 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new stake in shares of Evolent Health in the 3rd quarter valued at approximately $156,000. Institutional investors own 95.38% of the company’s stock.
Several equities research analysts recently commented on the stock. Cantor Fitzgerald reiterated a “buy” rating and set a $30.00 target price on shares of Evolent Health in a research report on Sunday, December 3rd. Leerink Swann set a $25.00 target price on shares of Evolent Health and gave the stock a “buy” rating in a research report on Saturday, November 18th. Goldman Sachs Group downgraded shares of Evolent Health from a “conviction-buy” rating to a “buy” rating in a research report on Tuesday, November 7th. SunTrust Banks reiterated a “buy” rating and set a $30.00 target price on shares of Evolent Health in a research report on Friday, November 3rd. Finally, Robert W. Baird reiterated a “buy” rating and set a $25.00 target price on shares of Evolent Health in a research report on Wednesday, November 1st. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and thirteen have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $28.00.
Evolent Health (NYSE:EVH) last issued its quarterly earnings results on Thursday, November 2nd. The technology company reported ($0.04) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.04. The firm had revenue of $107.90 million for the quarter, compared to the consensus estimate of $104.49 million. Evolent Health had a negative net margin of 15.86% and a negative return on equity of 5.05%. The company’s revenue for the quarter was up 79.2% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.26) EPS. analysts expect that Evolent Health Inc will post -0.57 earnings per share for the current fiscal year.
About Evolent Health
Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.
Receive News & Stock Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related stocks with our FREE daily email newsletter.